Chronic Kidney Disease (CKD) is a major health problem which affects up to 12% of the population and is on the rise globally. The primary treatment, haemodialysis puts constant pressure on healthcare systems, the speed of transplants cannot keep up with demand and not every patient is eligible for a transplant. Therefore, at-home peritoneal dialysis (PD) is increasingly used as a better option, both financially and for quality of life, as it limits time in hospital and gives patients more freedom. Unfortunately, PD is not currently a permanent treatment option; complications can arise, such as peritoneal infections (peritonitis) and immune cell-driven fibrosis (scarring of peritoneal membranes). Therefore, research that addresses the function of immune cells in PD is likely to improve the longevity of treatment, decrease the burden on health systems and improve the quality of life of patients. PD functions by using a peritoneal catheter to fill and drain the peritoneal cavity with approximately 2 litres of dialysis fluid - a basic mixture of sugar and stabilisers designed only to draw waste metabolites from the blood. My previous research has shown that vital immune cells in peritoneum require a broader range of metabolites to perform their anti-microbial function, including amino acids such as glutamate. Currently, the health and function of immune cells are currently not considered in PD. This project will investigate the benefits of metabolite alteration of PD fluid (e.g. addition of glutamate) to promote cell health and immune defence, which will prevent the poor outcomes of PD. The goals of this project to define the best additives for peritoneal dialysis fluid that improves the longevity of this treatment option for patients, and to determine whether altering the metabolism of immune cells can treat peritonitis.

Translational control of localized mRNAs is a common mechanism for regulating protein expression in specific cellular subdomains and plays an important role in a number of processes, such as axes formation, asymmetric cell division, cell motility, and neuronal synaptic plasticity (1-3). Localized mRNAs are usually transported in ribonucleoprotein particles (RNPs) and must be translationally repressed until the RNA reaches its final destination. This is achieved by translational repressor molecules, e.g. Bruno, CPEB,eIF4AIII, FMRP, Staufen and ZBP1 that are present in these transport RNPs. It has recently emerged that mRNA degradation factors also play an essential role in mRNA localization. For example, the transport of oskar (osk) mRNA to the posterior of the Drosophila oocyte requires the DEAD-box RNA helicase Me31b/DDX-6, a decapping activator, and the Dcp-1 subunit of the decapping enzyme that removes the 5'-cap from mRNAs to trigger their degradation. Both proteins colocalize with osk mRNA at the oocyte posterior. Furthermore, osk mRNA localization also depends on the exon junction complex (EJC) and Staufen, both of which have been implicated in mRNA decay in mammals. The EJC must be bound to an mRNA downstream of a stop codon to trigger nonsense mediated decay (NMD), while Staufen 1 recruits the NMD factor Upf1 to specific mRNA 3'-UTRs and thereby induces a novel form of mRNA decay. In mammals, Staufen 1 is a component of dendritic mRNA transport complexes. Moreover, the DEAD-box protein DDX-6, the mammalian homolog of Me31b, is found in kinesin-associated RNA granules isolated from rat brain. osk mRNA localization is also disrupted by mutations in armitage (armi), spindle-E (spn-E) and maelstrom, all RISC components mediating siRNA-dependent RNA degradation and miRNA-dependent translational silencing. In contrast, the Argonaute proteins, Aubergine (Aub) and Piwi, are required for efficient osk mRNA translation once it is localized, and both proteins accumulate at the posterior with the mRNA. Both proteins have been shown to associate with a new class of small RNAs called repeat-associated small interfering RNAs (rasiRNAs) to repress the activity of transposable elements in the germline. However, it is unclear whether Aub and Piwi that localize with osk mRNA are bound to rasiRNAs, nor whether the latter play any role in osk mRNA translation or degradation.Finally, there is recent evidence that not only RNA degradation but also translational silencing is coupled to RNA transport in mammals, since non-coding RNAs, such as microRNAs (miRNAs) and longer regulatory RNAs, e.g. BC1, can repress translation of mRNAs during transport (22-24). It has been postulated that this miRNA-guided silencing occurs in another class of RNPs, called processing bodies (Pbodies),which are the major sites of mRNA degradation in both invertebrate and vertebrate cells , and that repressed mRNAs can even be released from P-bodies upon specific signals into the cytoplasm for further translation. This raises the question of whether P-bodies provide a platform for the transport of translationally repressed RNAs, and function as centers that co-ordinate degradation, translation and localization. We would therefore like to investigate whether P-body components are involved in mRNA transport by addressing the following specific questions: Do protein components of the RNA degradation pathway and the RISC complex play a direct role in localizing RNAs in Drosophila oocytes or mammalian neurons? Do small non-coding RNAs silence mRNA during their transport in both systems? Do localized mRNAs associate with P-bodies, before, during or after their transport to their destination? What is the molecular function of the Argonaute family members Aub and Piwi in osk mRNA localization and translation in Drosophila oocytes? Are individual members of the mammalian Ago family, e.g. Ago1-5, associated with specific miRNAs in dendritic RNPs?